Viridian Therapeutics(VRDN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) remains on track for topline readout in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial in chronic TED topline readout expected year-end 2024; enrollment completed in July and exceeded its target - - REVEAL-1 and REVEAL-2, global phase 3 clinical trials for subcutaneous VRDN-003 in patients with ...